Showing results (71-80 of 93) with videos related to
Sort By:
Pageof 10
Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy|November 27, 2012
Clinical and bacteriological efficacies of sitafloxacin against community-acquired pneumonia caused by Streptococcus pneumoniae: nested cohort within a multicenter clinical trialJiro Fujita, Yoshihito Niki, Jun-Ichi Kadota, et al.The Kobe Journal of Medical Sciences|September 3, 2008
Reversal effects of Ca2+ antagonists on multidrug resistance via down-regulation of MDR1 mRNAChiho Komoto, Tsutomu Nakamura, Motohiro Yamamori, et al.Drug Metabolism and Pharmacokinetics|January 6, 2009
Population pharmacokinetics of landiolol hydrochloride in healthy subjectsNaoki Honda, Susumu Nakade, Hidefumi Kasai, et al.Oncology Reports|July 3, 2010
Pharmacokinetics of S-1 and CYP2A6 genotype in Japanese patients with advanced cancerTakashi Hirose, Ken-Ichi Fujita, Kazuko Nishimura, et al.The Journal of Biological Chemistry|June 3, 2011
Lowering bile acid pool size with a synthetic farnesoid X receptor (FXR) agonist induces obesity and diabetes through reduced energy expenditureMitsuhiro Watanabe, Yasushi Horai, Sander M Houten, et al.Cancer Chemotherapy and Pharmacology|November 26, 2005
Phase I and pharmacokinetic study of edotecarin, a novel topoisomerase I inhibitor, administered once every 3 weeks in patients with solid tumorsYasuhide Yamada, Tomohide Tamura, Noboru Yamamoto, et al.Japanese Journal of Clinical Oncology|May 11, 2006
Phase I/II study of oxaliplatin with weekly bolus fluorouracil and high-dose leucovorin (ROX) as first-line therapy for patients with colorectal cancerYasuhide Yamada, Atsushi Ohtsu, Narikazu Boku, et al.Japanese Journal of Cancer Research : Gann|October 3, 2002
Thalidomide for the treatment of refractory multiple myeloma: association of plasma concentrations of thalidomide and angiogenic growth factors with clinical outcomeTsunayuki Kakimoto, Yutaka Hattori, Shinichiro Okamoto, et al.Journal of Human Genetics|October 4, 2013
Polymorphisms in the UGT1A1 gene predict adverse effects of irinotecan in the treatment of gynecologic cancer in Japanese patientsAkira Hirasawa, Takeru Zama, Tomoko Akahane, et al.Cancer Chemotherapy and Pharmacology|February 11, 2020
Evaluation of gefitinib systemic exposure in EGFR-mutated non-small cell lung cancer patients with gefitinib-induced severe hepatotoxicityTakahisa Kawamura, Chiyo K Imamura, Hirotsugu Kenmotsu, et al.Pageof 10